Banking and financial services professional with over 12 years experience. Like to trade and invest, solid companies with potential, undiscovered, undervalued. Looking for the next Apple.
Banking and financial services professional with over 12 years experience. Like to trade and invest, solid companies with potential, undiscovered, undervalued. Looking for the next Apple.
less
Latest Comments
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
Trevor, please see my reply to Mike Faragut below. In regards to your hypothetical question on rejection, note that the FDA's advisory board recommended approval of the drug back in 2007. The FDA then issued them an "approvable" letter in Aug '08. This is all before the partnership with Merck and the subsequent approval and launch in the EU. See:
www.cardiome.com/.../cardiome-and-astellas-announce-receipt-fda-approvable-letter-kynapid
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
No, I'd say it was firmly down to a lack of intelligence
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
They're concentrating on IV for now as it as approved. Oral is the next step
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
The world outside the US is a big enough market. As stated in the article, the company is expanding in Europe, South America, China.. They don't need the US market to be profitable
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
I'm guessing lack of server space? It was up until recently, I think they just pull down older stuff no longer getting traffic.